|本期目录/Table of Contents|

[1]彭雨.索拉非尼联合FOLFOX4 化疗治疗晚期原发性肝癌的前瞻性临床研究[J].慢性病学杂志,2018,(05):525-527.
　PENG Yu.Prospective clinical research of sorafenib combined with FOLFOX4 chemotherapy on patients with advanced primary liver cancer[J].,2018,(05):525-527.
点击复制

索拉非尼联合FOLFOX4 化疗治疗晚期原发性肝癌的前瞻性临床研究(PDF)

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:
期数:
2018年05期
页码:
525-527
栏目:
论著
出版日期:
2018-05-20

文章信息/Info

Title:
Prospective clinical research of sorafenib combined with FOLFOX4 chemotherapy on patients with advanced primary liver cancer
作者:
彭雨
江门市中心医院肿瘤二区，广东江门529000
Author(s):
PENG Yu
Oncology ward Two, Jiangmen Central Hospital, Jiangmen 529000，China Corresponding author: PENG Yu, E-mail: 1137129631@qq.com
关键词:
原发性肝癌; 晚期; FOLFOX4化疗; 索拉非尼
Keywords:
Primary liver cancer;  Advanced stage;  FOLFOX4 Chemotherapy;  Sorafenib
分类号:
R735.7
DOI:
-
摘要:
目的奥沙利铂为铂类新型药物，与氟尿嘧啶和亚叶酸钙联合构成的FOLFOX4 化疗方案已在肝癌治疗 中得到认可。探讨索拉非尼联合FOLFOX4 化疗治疗晚期原发性肝癌的前瞻性临床研究。方法随机选取 2016 年4 月—2017 年12 月江门市中心医院收治的80 例晚期原发性肝癌患者进行研究，根据入院顺序单双号分为 观察组和对照组，每组40 例。其中，对照组采用FOLFOX4 化疗治疗，观察组采用索拉非尼联合FOLFOX4 化 疗治疗，14 d 为1 个周期，两组均持续治疗8 个周期。观察两组患者治疗状况，比较不良反应、疗效、患者生存 时间。结果治疗前两组患者血清甲胎蛋白（AFP） 指标比较，差异无统计学意义（P>0.05）；治疗后，观察 组低于对照组，差异有统计学意义（P<0.05）。观察组治疗总疗效率为82.50%，高于对照组的57.50%，差异有 统计学意义（P<0.05）。观察组不良反应总发生率为17.50%，低于对照组的20.00%，差异无统计学意义（P> 0.05）。结论索拉非尼联合FOLFOX4化疗可明显提升肝癌的治疗疗效。
Abstract:
Objective Sorafenib is a new type of platinum drugs. FOLFOX4 chemotherapy included Sorafenib combined Fluorouracil and Calcium folinate was identified in the treatment of liver cancer. This subject was to analyze the effect of sorafenib combined with FOLFOX4 chemotherapy on patients with advanced primary liver cancer by prospective clinical research. Methods Totally 80 cases of patients with advanced primary liver cancer were enrolled who were treated in Jiangmen Central Hospital from April 2016 to December 2017. Subjects were randomly divided into the study group and the control group according to the admission order. The control group received FOLFOX4 chemotherapy, while the study group received sorafenib combined with FOLFOX4 chemotherapy, the one treatment cycle was 14 days, and the treatment times in the two group were all 8 cycles. Then, the treatment status of patients in two groups were observed and compared, such as adverse reaction, clinical effect, patient's survival time. Results There was not significantly different in the serum AFP level in the two groups （P>0.05） . After the treatment, AFP level in the study group was significantly lower than that in the control group （P<0.05） . The total clinical effect in the study group was 82.50%, which was significantly higher than that in the control group of 57.50%, and P<0.05. The total adverse reaction rate in the study group was 20.00%, which in the control group was 17.50%, and there was notsignificantly different between them （P>0.05） . Conclusion The sorafenib combined with FOLFOX4 chemotherapy can significantly improve the treatment effect.

参考文献/References:

[1] 姚红,于雷,钟丽华,等.DKK-1 与肝脏恶性肿瘤的相关研究进展 [J].现代生物医学进展,2016,16(10):1962-1965.
[2] Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide [J]. J Hepatol, 2006,45(4):529-538.
[3] 杨学芳,李雷,沈世林,等. 索拉非尼治疗晚期原发性肝癌的研究 现状[J].医学综述,2016,22(5):918-920,921.
[4] 邢爱丽,王洋,李威,等. 索拉非尼联合肝动脉化疗栓塞治疗原发 性肝癌的研究进展[J].实用医学杂志,2017,33(14):2251-2254.
[5] 杨学宁,吴一龙.实体瘤治疗疗效评价标准-RECIST[J]. 循证医 学,2004,4(2):85-90.
[6] 陈珑,梁冬,候本新,等. 索拉非尼联合希罗达治疗三亚地区回、 汉族中晚期原发性肝癌患者的疗效对比分析[J]. 临床肝胆病杂 志,2015,31(6):895-898.
[7] 郭列平. 节律性化疗在晚期肝细胞肝癌中的应用进展[J]. 中国肿 瘤临床,2017,44(18):948-952.
[8] 王哲,何德山,任柯,等. 中晚期原发性肝癌患者的治疗方案对比 研究[J].中国现代普通外科进展,2016,19(1):69-72.
[9] 赵瑜.索拉非尼为主的化疗方案治疗晚期原发性肝细胞癌的疗效 观察[J].现代实用医学,2015,27(4):475-476,481.
[10] 沈永奇,黄军,陈超庭,等. 雷替曲塞联合奥沙利铂与FOLFOX4 方案治疗中晚期原发性肝癌的疗效评价[J]. 实用临床医药杂志, 2017,21(7):39-42.

备注/Memo

备注/Memo:
基金项目：江门市卫生和计划生育局医学科研课题（201646A002） 作者简介：彭雨，硕士研究生，中级，肝癌肺癌的分子靶向治疗与放化疗的综合治疗 通信作者：彭雨，E-mail: 1137129631@qq.com
更新日期/Last Update: 2018-05-28